Immune Response News and Research

RSS

COVID-19 recovered vaccinated individuals more protected from Delta variant

The B.1.617 lineage of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in October 2020, has led to new outbreaks of the infection and new waves of the pandemic. This infectious lineage has resulted in the generation of sub-lineages such as B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.617.3.

6 Jul 2021

Dimeric IgA antibodies help identify recent SARS-CoV-2 infection

A fascinating new study, released as a preprint on the medRxiv* server, adds a highly appealing tool to the armory of detection techniques for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its validation could allow the early and accurate detection of recent or active infection, which is valuable in tracing contacts and preventing forward transmission of the virus.

5 Jul 2021

Rapid quantification of SARS-CoV-2 Spike-specific T cells by direct peptide stimulation of whole peripheral blood

To understand both the correlates of protection induced by vaccinations and the necessary immune responses to manage the COVID-19, researchers from Singapore used an alternative method to closely evaluate the kinetics and magnitude of specific T cell responses to SARS-CoV-2 infection. Their work was posted to the bioRxiv* preprint server while awaiting peer review.

5 Jul 2021

Janssens’ COVID-19 vaccine effective against SARS-CoV-2 Delta variant

Researchers in the Netherlands have conducted a study showing that Janssen’s Ad26.COV2.S coronavirus disease 2019 (COVID‐19) vaccine was effective against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among eight individuals.

4 Jul 2021

COVID-19 vaccination induces highly variable immunity among the immunocompromised

Researchers in the United States have conducted a study showing that the humoral (antibody) immunity induced by vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – varies significantly among immunocompromised individuals.

4 Jul 2021

Structure-guided T cell vaccine design could offer broad protection SARS-CoV-2 variants

Gaurav Gaiha, MD, DPhil, a member of the Ragon Institute of MGH, MIT and Harvard, studies HIV, one of the fastest-mutating viruses known to humankind.

2 Jul 2021

Research pinpoints a molecular component responsible for modulating flu damage

New experimental data pinpoints a molecular component responsible for modulating the damage the flu can wreck on the lungs.

2 Jul 2021

Salivary markers of oxidative stress during severe COVID-19

An interesting study from researchers at the University of Sharjah, Sharjah, United Arab Emirates, presents evidence that an elevated level of expression of oxidant molecules may be correlated with severe infection and lung injury.

2 Jul 2021

B cell depleting agents can cause altered immune responses to COVID-19 vaccines, suggests study

A new preprint, available on the medRxiv* server, describes altered responses to the use of the highly effective messenger RNA (mRNA) vaccines from Pfizer/BioNTech and Moderna in patients with multiple sclerosis on anti-CD20 (MS-aCD20) monotherapy.

2 Jul 2021

Stool transplant may be worth exploring as treatment option for COVID-19

It might be worth exploring stool transplant to treat COVID-19 infection, suggest doctors in a letter published online in the journal Gut, after they used the procedure in two patients to prevent the recurrence of another bacterial infection.

2 Jul 2021

New immunotherapy treatment for cancer patients is more effective and less dangerous

Cell toxicity during immunotherapy is a major limitation to cancer treatment.

2 Jul 2021

Researchers seek to quantify immunogenicity of COVID vaccines in immunocompromised patients

Evidence continues to mount that vaccination against COVID-19, most notably the Pfizer and Moderna vaccines, produces robust, durable protection in the vast majority of recipients.

2 Jul 2021

Is there a link between circadian rhythms and COVID-19 severity?

This study showed that the time of day of SARS-CoV-2 infection could impact the severity of the viral infection and the host immune response.

1 Jul 2021

Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cells

In a paper recently uploaded to the preprint server bioRxiv* by Schamel et al. (June 25th, 2021) engineered T cells against SARS-CoV-2 are tested against a range of cells in vitro, finding that the treatment could be used to restore cellular immune function and suppress SARS-CoV-2.

1 Jul 2021

Mutations in the spike proteins of SARS-CoV-2 select for amino acid changes, increasing protein stability

A team of researchers recently demonstrated that mutations in the S protein of SARS-CoV-2 select for amino acid changes that result in a more stable protein than would otherwise be expected.

1 Jul 2021

Study highlights the importance of T cell cross reactivity in stopping severe COVID-19 infections

Researchers at La Jolla Institute for Immunology have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.

1 Jul 2021

Scientists uncover features of T cells that distinguish fatal COVID-19 from non-fatal cases

While vaccines are doing a remarkable job of slowing the COVID-19 pandemic, infected people can still die from severe illness and new medications to treat them have been slow to arise.

1 Jul 2021

Can age, sex, BMI or blood group influence the immunogenicity of the Pfizer/BioNTech COVID-19 vaccine?

A group of Belgium researchers recently discuss their findings in the journal Microorganisms, which describe the influence of several factors on vaccine-induced immunogenicity.

1 Jul 2021

COVID-19 vaccines are effective in 94% of cancer patients, shows study

In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.

1 Jul 2021

Researchers identify proteins that contribute to the pathogenicity of COVID-19 virus

Researchers at Texas Biomedical Research Institute (Texas Biomed) have narrowed down the proteins enabling SARS-CoV-2 to cause disease.

1 Jul 2021

Immune Response News and Research

COVID-19 recovered vaccinated individuals more protected from Delta variant

Dimeric IgA antibodies help identify recent SARS-CoV-2 infection

Rapid quantification of SARS-CoV-2 Spike-specific T cells by direct peptide stimulation of whole peripheral blood

Janssens’ COVID-19 vaccine effective against SARS-CoV-2 Delta variant

COVID-19 vaccination induces highly variable immunity among the immunocompromised

Structure-guided T cell vaccine design could offer broad protection SARS-CoV-2 variants

Research pinpoints a molecular component responsible for modulating flu damage

Salivary markers of oxidative stress during severe COVID-19

B cell depleting agents can cause altered immune responses to COVID-19 vaccines, suggests study

Stool transplant may be worth exploring as treatment option for COVID-19

New immunotherapy treatment for cancer patients is more effective and less dangerous

Researchers seek to quantify immunogenicity of COVID vaccines in immunocompromised patients

Is there a link between circadian rhythms and COVID-19 severity?

Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cells

Mutations in the spike proteins of SARS-CoV-2 select for amino acid changes, increasing protein stability

Study highlights the importance of T cell cross reactivity in stopping severe COVID-19 infections

Scientists uncover features of T cells that distinguish fatal COVID-19 from non-fatal cases

Can age, sex, BMI or blood group influence the immunogenicity of the Pfizer/BioNTech COVID-19 vaccine?

COVID-19 vaccines are effective in 94% of cancer patients, shows study

Researchers identify proteins that contribute to the pathogenicity of COVID-19 virus

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News